MAPK Signaling
MAPK Signaling(MAPK信号通路)
MAPK Signaling 相关产品(575)
- GC45064Tomatidine (hydrochloride)CAS: 6192-62-7纯度: >98.00%
A steroidal alkaloid with diverse biological activities
- GC45067Tpl2 Kinase InhibitorCAS: 871307-18-5纯度: >95.00%
Tpl2 Kinase Inhibitor（TKI）是一种可透过细胞膜的萘啶化合物，作为Tpl2激酶强效可逆的，ATP竞争性的抑制剂。
- GC46123Comprehensive Kinase Screening Library纯度: >98.00%
For screening of a variety of kinase inhibitors
- GC465542'-O-Monosuccinyladenosine-3',5'-cyclic monophosphateCAS: 36940-87-1纯度: >98.00%
An immunogenic derivative of cAMP
- GC46957Bumetanide-d5CAS: 1216739-35-3纯度: >99.00%
An internal standard for the quantification of bumetanide
- GC47045Carvedilol-d5CAS: 929106-58-1纯度: >99.00%
An internal standard for the quantification of carvedilol
- GC47088Cilostazol-d4CAS: 1215541-47-1纯度: >99.00%
An internal standard for the quantification of cilostazol
- GC47166Dabrafenib-d9CAS: 1423119-98-5纯度: >99.00%
An internal standard for the quantification of dabrafenib
- GC47237Dipyridamole-d16CAS: 2712261-50-0纯度: >99.00%
A neuropeptide with diverse biological activities
- GC48469Moexipril-d5CAS: 1356929-49-1纯度: >99.00%
An internal standard for the quantification of moexipril
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC44852 | Rp-8-bromo-Cyclic AMPS (sodium salt) | 925456-59-3 | - | |
An antagonist of cAMP-dependent PKAs | ||||
| GC44853 | Rp-8-CPT-Cyclic AMP (sodium salt) | 221905-35-7 | >98.00% | |
A PKA inhibitor | ||||
| GC44917 | Sorafenib N-oxide | 583840-03-3 | >98.00% | |
An active metabolite of sorafenib | ||||
| GC44920 | Sp-8-bromo-Cyclic AMPS (sodium salt) | 1573115-90-8 | >98.00% | |
A PKA activator | ||||
| GC45064 | Tomatidine (hydrochloride) | 6192-62-7 | >98.00% | |
A steroidal alkaloid with diverse biological activities | ||||
| GC45067 | Tpl2 Kinase Inhibitor | 871307-18-5 | >95.00% | |
Tpl2 Kinase Inhibitor（TKI）是一种可透过细胞膜的萘啶化合物，作为Tpl2激酶强效可逆的，ATP竞争性的抑制剂。 | ||||
| GC45099 | U-0126 | 109511-58-2 | >98.00% | |
A MEK inhibitor and AMPK activator | ||||
| GC45902 | Trametinib-13C-d3 | - | >99.00% | |
A neuropeptide with diverse biological activities | ||||
| GC46015 | KY 05009 | 1228280-29-2 | >99.50% | |
A TNIK inhibitor | ||||
| GC46123 | Comprehensive Kinase Screening Library | - | >98.00% | |
For screening of a variety of kinase inhibitors | ||||
| GC46554 | 2'-O-Monosuccinyladenosine-3',5'-cyclic monophosphate | 36940-87-1 | >98.00% | |
An immunogenic derivative of cAMP | ||||
| GC46808 | ADTL-EI1712 | 2414916-45-1 | >98.00% | |
A dual ERK1 and ERK5 inhibitor | ||||
| GC46957 | Bumetanide-d5 | 1216739-35-3 | >99.00% | |
An internal standard for the quantification of bumetanide | ||||
| GC47045 | Carvedilol-d5 | 929106-58-1 | >99.00% | |
An internal standard for the quantification of carvedilol | ||||
| GC47088 | Cilostazol-d4 | 1215541-47-1 | >99.00% | |
An internal standard for the quantification of cilostazol | ||||
| GC47166 | Dabrafenib-d9 | 1423119-98-5 | >99.00% | |
An internal standard for the quantification of dabrafenib | ||||
| GC47237 | Dipyridamole-d16 | 2712261-50-0 | >99.00% | |
A neuropeptide with diverse biological activities | ||||
| GC47771 | NG 25 (hydrochloride hydrate) | - | >98.00% | |
An inhibitor of MAP4K2 and TAK1 | ||||
| GC47931 | PDE4B Inhibitor | 2410550-31-9 | >98.00% | |
A PDE4B inhibitor | ||||
| GC48329 | PKA Inhibitor (5-24) (trifluoroacetate salt) | - | >95.00% | |
A synthetic peptide inhibitor of PKA | ||||
| GC48381 | 5'-pApA (sodium salt) | - | >95.00% | |
A linearized form of cyclic di-AMP | ||||
| GC48469 | Moexipril-d5 | 1356929-49-1 | >99.00% | |
An internal standard for the quantification of moexipril | ||||
| GC48652 | Olomoucine II | 500735-47-7 | >98.00% | |
A CDK inhibitor | ||||
| GC48870 | Anagrelide-13C3 | - | >98.00% | |
An internal standard for the quantification of anagrelide | ||||